Current Report Filing (8-k)
December 15 2020 - 05:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9,
2020
MITESCO, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
000-53601
|
|
87-0496850
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
7535 East Hampden Avenue, Ste. 400
Denver, Colorado 80231
|
(Address of principal executive offices) (Zip Code)
|
(844) 383-8689
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01
|
Entry into Material Definitive Agreement
|
Sale and Issuance of Eagle Equities, LLC Term Note
Mitesco, Inc. (the “Company”) entered into a Securities Purchase
Agreement (the “SPA”) and 12% Convertible Redeemable Note due
December 9, 2021 (the “Note”), each dated December 8, 2020, and
funded on December 9 2020, with Eagle Equities, LLC. The
aggregate principal amount of the new note is $220,000, it carries
a 12% interest rate and has a maturity date of twelve (12) months
from the date of execution. The Company may prepay the note, and
management intends to fulfill this option, at a premium of 110% to
140% of principal and interest between the date of issuance and 180
days thereafter. Should the note not be paid in full, any remaining
balance, at any time after 180 days after issuance may be
convertible into the Company’s common stock at a conversion price
for each share of common stock equal to 70% of the lowest traded
price of the Company's common stock for the 20 prior trading days
including the day upon which a notice of conversion is received by
the Company.
Item 1.01 of this Current Report on Form 8-K contains only a brief
description of the material terms of the Note and SPA, and does not
purport to be a complete description of the rights and obligations
of the parties thereunder, and such descriptions are qualified in
their entirety by reference to the full text of the Note and
SPA, filed as Exhibits 4.01 and 10.01, respectively, to this
Current Report on Form 8-K, and are incorporated herein by
reference.
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under
an Off-Balance Sheet Arrangement of a Registrant.
|
The information set forth under Item 1.01 above with respect to the
Company entering into the Note with Eagle Equities, LLC is hereby
incorporated by reference into this Item 2.03, insofar as it
relates to the creation of a direct financial obligation of the
Company.
Item 3.02
|
Unregistered Sales of Equity Securities.
|
The applicable information set forth in Item 1.01 of this Current
Report on Form 8-K is incorporated by reference in this Item 3.02.
The issuance of the securities set forth herein was made in
reliance on the exemption provided by Section 4(a)(2) of the
Securities Act for the offer and sale of securities not involving a
public offering. The recipient of the Note is an accredited
investor.
Item 7.01
|
Regulation FD Disclosure.
|
On October 15, 2020, the Company issued a press announcing that it
has entered into two (2) letters of intent with Lennar Corporation
which call for the expansion of its “The Good Clinic” business
operation into the Denver, Colorado marketplace.
A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information presented in Item 7.01 of this Current Report on
Form 8-K and Exhibit 99.1 is being furnished and shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise be subject to the liabilities of
that section, nor is it incorporated by reference into any filing
of the Company, under the Securities Act of 1933, or the Securities
Exchange Act of 1934, whether made before or after the date hereof,
regardless of any general incorporation language in such
filing.
Plans to expand “The Good Clinic” into the Denver, Colorado
marketplace
The Company has executed two (2) Letter of Intent agreements with a
division of Lennar Corporation calling for the expansion of its
“The Good Clinic” operations into two (2) sites being developed by
Lennar in the Denver, Colorado marketplace. The Company has
previously announced its nationwide expansion plans to include up
to fifty (50) clinic sites over the next three (3) years,
contingent on the availability of suitable financing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
MITESCO, INC.
|
|
|
|
Date: December 15, 2020
|
By:
|
/s/ Lawrence Diamond
|
|
|
|
Lawrence Diamond
|
|
|
Chief Executive Officer and Interim Chief Financial
Officer
|